LABORATORY RESEARCH USE ONLY. NOT INTENDED FOR CONSUMPTION.

AOD-9604 — Published Research

Reviewed by: James S.| Last updated: April 28, 2026|For laboratory reference only

← Back to AOD-9604 product page

Research Library

Published research on AOD-9604 — for educational purposes only

HGH Fragment 177-191 Structure and Mechanism

The C-terminal fragment of human GH (residues 177–191) was identified through structure-function studies as a region involved in lipolytic activity. Unlike full-length GH, the fragment does not bind to the GH receptor (GHR), does not stimulate IGF-1 production, and does not induce longitudinal bone growth. Research suggests the fragment may interact with beta-3 adrenergic receptors on adipocytes or act through an as-yet-unidentified receptor distinct from GHR. The lipolytic domain is conformationally distinct from the somatogenic (growth-promoting) domains of GH. For laboratory research use only.

Ng FM et al. “Metabolic studies of a synthetic lipolytic domain (AOD9604) of HGH 191AA.” Horm Res. 2000. PubMed

AOD-9604 in Adipocyte Lipid Metabolism Models

In vitro studies using 3T3-L1 adipocytes demonstrated that AOD-9604 stimulated lipolysis (glycerol release) and inhibited lipogenesis (fatty acid incorporation into triglycerides). The anti-lipogenic effect appears to involve suppression of acetyl-CoA carboxylase and fatty acid synthase enzyme activities. In obese mouse models, chronic AOD-9604 exposure did not alter IGF-1 levels or glucose/insulin homeostasis markers, consistent with its lack of GHR binding. For laboratory research use only.

Heffernan MA et al. “The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic exposure in obese mice and beta(3)-AR knock-out mice.” Endocrinology. 2001. PubMed

AOD-9604 Preclinical Safety Profile

Preclinical safety characterization of AOD-9604 included standard genotoxicity assays (Ames test, chromosomal aberration assay, micronucleus test), all of which showed no mutagenic activity. Chronic exposure studies in rodent models monitored hematology, clinical chemistry, and IGF-1 levels to confirm the absence of GH-like somatogenic activity. The safety data support AOD-9604’s classification as a non-GHR-binding peptide fragment. For laboratory research use only.

Stier H et al. “Safety of AOD9604 in a comprehensive preclinical assessment.” J Metabolic-dysregulation models Eating Disord. 2019. J Obes Eat Disord

Continue reviewing AOD-9604

Use the research references above alongside Panda’s batch documentation and catalog specifications.

Disclaimer: All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use only. This page is provided for research-reference and documentation review only.

Reviewed by

James S.

Research content reviewer focused on peptide literature summaries, source quality, and reference clarity.

Editorial Review

Reviewed by Elizabeth D. and James S. — Panda Peptides Research Team.

Last reviewed: May 2026.

This content summarizes published laboratory literature for research-reference purposes only. Products referenced by Panda Peptides are sold strictly for controlled laboratory, analytical, or reference use and are not consumer products.